Physician profile
Meredith Gentry
NPI 1295315273
$3,672.86
in general payments reported to CMS, 2019-2025
30 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $238 · 2023: $491 · 2024: $1,497 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.43 | 2023-2025 | |
| Lilly USA, LLC | $317.71 | 2023-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $245.36 | 2023-2025 | Vyepti, Rexulti |
| Ucb, INC. | $210.28 | 2022-2025 | Nayzilam, Briviact |
| Pfizer INC. | $207.39 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $185.33 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $184.52 | 2023-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $183.34 | 2023-2025 | |
| Catalyst Pharmaceuticals, INC. | $183.24 | 2023-2025 | Fycompa |
| Eisai INC. | $179.21 | 2023-2025 | |
| Neurelis, INC. | $166.64 | 2023-2025 | Valtoco |
| Kyowa Kirin, INC. | $166.38 | 2023-2024 | Nourianz |
| Otsuka America Pharmaceutical, INC. | $152.61 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $121.16 | 2022 | |
| Amneal Pharmaceuticals LLC | $107.99 | 2024-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $105.51 | 2023-2025 | Nuplazid |
| Astrazeneca Pharmaceuticals Lp | $70.98 | 2023-2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $64.14 | 2024-2025 | Austedo Xr, Ajovy |
| Averitas Pharma INC. | $54.35 | 2025 | Qutenza |
| Octapharma USA, INC. | $50.78 | 2024-2025 | Panzyga |
| Aucta Pharmaceuticals, INC. | $50.00 | 2024-2025 | Motpoly Xr |
| Janssen Biotech, INC. | $46.03 | 2025 | |
| Tanabe Pharma America, INC. | $45.88 | 2024-2025 | Radicava |
| Amgen INC. | $38.61 | 2024 | Aimovig |
| Jazz Pharmaceuticals INC. | $32.10 | 2024 | |
| Cala Health, INC. | $26.24 | 2022 | |
| Axsome Therapeutics, INC. | $22.71 | 2025 | Symbravo |
| Alnylam Pharmaceuticals INC. | $21.16 | 2025 | Amvuttra |
| Alexion Pharmaceuticals, INC. | $19.50 | 2024 | Ultomiris |
| Genentech USA, INC. | $16.28 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Gentry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.